Abstract

NeoGenomics will report second-quarter 2026 results on July 28, 2026 Post-Mkt; this preview summarizes market forecasts for revenue, gross margin, net margin, and adjusted EPS, reviews last quarter’s results, and compiles prevailing analyst expectations and key business drivers for the upcoming print.

Market Forecast

Consensus points to second-quarter revenue of 196.997 million US dollars, implying 7.83% year-over-year growth, an estimated adjusted EPS of 0.03, and an EBIT loss of 19.03 million US dollars; year-over-year adjusted EPS growth is projected at 45.33%. Margin expectations embed a continued recovery in profitability with a focus on cost leverage, although an EBIT loss remains. The company’s core clinical testing business is expected to lead revenue with stable volume growth and a revenue mix still skewed toward client-direct billing; the outlook emphasizes throughput expansion and improved reimbursement dynamics. The most promising segment remains client-direct billing at 131.61 million US dollars last quarter, with ongoing year-over-year growth supported by volume and test menu expansion.

Last Quarter Review

NeoGenomics reported revenue of 186.67 million US dollars, a gross profit margin of 43.32%, a GAAP net loss attributable to shareholders of 17.11 million US dollars with a net margin of -9.16%, and adjusted EPS of 0.01; revenue grew 11.09% year over year. A highlight was the company’s continued progress toward profitability as losses narrowed versus expectations, with EBIT better than forecast by 1.60 million US dollars. Main business revenues were led by client-direct billing at 131.61 million US dollars, commercial insurance at 30.94 million US dollars, and Medicare and other government at 24.15 million US dollars; the revenue mix suggests stronger enterprise and institutional demand.

Current Quarter Outlook

Core clinical testing business

The company’s core clinical testing franchise should remain the primary revenue driver this quarter, underpinned by double-digit volume trends exiting the prior quarter and continued adoption of oncology assays. Market expectations anchor to 196.997 million US dollars in revenue, implying sustained mid-to-high single-digit year-over-year growth off a strong comparable base. Gross margin execution will be watched closely after last quarter’s 43.32%, as throughput efficiency and mix shift toward higher-complexity tests are key to offsetting wage, reagent, and logistics inflation. Reimbursement stability is a swing factor; continued normalization in commercial payer policies and clean claim rates could help lift net revenue per test and support an improved net margin from last quarter’s -9.16%. Execution on lab automation and accessioning turn times will likely be focal points for investors seeking signals of scalability.

Client-direct billing and enterprise channels

Client-direct billing, which generated 131.61 million US dollars last quarter, remains the most promising revenue stream due to its scale, contracted relationships, and higher ordering consistency. Growth this quarter is expected to ride oncology care pathway expansion and cross-sell of advanced molecular tests, which can raise average revenue per order. Any incremental wins with large health systems or integrated delivery networks would support test volumes and potentially improve working capital cycles due to more predictable billing patterns. Operating leverage from higher fixed-cost absorption should aid gross margin, provided sample complexity does not outpace productivity gains. Watch for commentary on enterprise renewal rates and the cadence of new account activations as indicators for second-half momentum.

Key stock-price drivers this quarter

Three items are set to influence shares around the print: revenue growth cadence, margin trajectory, and updated outlook markers. On revenue, the 7.83% year-over-year estimate places a premium on stable test volumes and minimal reimbursement noise; any upside surprise from case mix or new customer ramps could shift sentiment quickly. On margins, investors will focus on whether gross margin can advance from last quarter’s 43.32% while narrowing the EBIT loss toward the estimated -19.03 million US dollars; commentary on cost containment and productivity initiatives will be critical. Finally, color on pipeline conversion for advanced diagnostics and the pace of menu innovation could shape expectations for back-half growth and the pathway to sustained adjusted profitability.

Analyst Opinions

Across recent commentary, the balance of views skews bullish, with the majority of analysts emphasizing recovering revenue growth, disciplined cost control, and an improving adjusted EPS trajectory supported by scale in clinical testing. Positive stances highlight the estimated 45.33% year-over-year improvement in adjusted EPS to about 0.03 alongside an expected revenue print near 196.997 million US dollars, interpreting these as signs of operational leverage despite a forecast EBIT loss. Several well-followed institutions underscore the durability of oncology testing demand and the benefits of deepened health system relationships, citing enterprise wins and menu breadth as drivers of share gains. Bullish analysis also points to last quarter’s outperformance versus revenue and EBIT expectations as evidence the company is on track with its turnaround program, anticipating incremental gross margin expansion if mix and reimbursement cooperate. Overall, the prevailing view expects a constructive setup into July 28, 2026 Post-Mkt, contingent on confirmation of volume resilience, steady reimbursement, and continued progress in narrowing losses.